Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Identifieur interne : 001504 ( Main/Curation ); précédent : 001503; suivant : 001505Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Auteurs : Praveen Balabaskaran Nina [Inde] ; Aditya Prasad Dash [Inde]Source :
- Indian journal of public health [ 0019-557X ] ; 2020.
Descripteurs français
- KwdFr :
- Antibactériens (usage thérapeutique), Antipaludiques (administration et posologie), Antipaludiques (effets indésirables), Antipaludiques (usage thérapeutique), Association de médicaments (MeSH), Azithromycine (usage thérapeutique), Betacoronavirus (MeSH), Humains (MeSH), Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux).
- MESH :
- administration et posologie : Antipaludiques, Hydroxychloroquine.
- effets indésirables : Antipaludiques, Hydroxychloroquine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antibactériens, Antipaludiques, Azithromycine, Hydroxychloroquine.
- Association de médicaments, Betacoronavirus, Humains, Pandémies.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (therapeutic use), Antimalarials (administration & dosage), Antimalarials (adverse effects), Antimalarials (therapeutic use), Azithromycin (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Drug Therapy, Combination (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , administration & dosage : Antimalarials, Hydroxychloroquine.
- chemical , adverse effects : Antimalarials, Hydroxychloroquine.
- chemical , therapeutic use : Anti-Bacterial Agents, Antimalarials, Azithromycin, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Drug Therapy, Combination, Humans, Pandemics, SARS-CoV-2.
Abstract
Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.
DOI: 10.4103/ijph.IJPH_496_20
PubMed: 32496241
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001504
Links to Exploration step
pubmed:32496241Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?</title><author><name sortKey="Nina, Praveen Balabaskaran" sort="Nina, Praveen Balabaskaran" uniqKey="Nina P" first="Praveen Balabaskaran" last="Nina">Praveen Balabaskaran Nina</name><affiliation wicri:level="1"><nlm:affiliation>Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu</wicri:regionArea></affiliation></author><author><name sortKey="Dash, Aditya Prasad" sort="Dash, Aditya Prasad" uniqKey="Dash A" first="Aditya Prasad" last="Dash">Aditya Prasad Dash</name><affiliation wicri:level="1"><nlm:affiliation>Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32496241</idno><idno type="pmid">32496241</idno><idno type="doi">10.4103/ijph.IJPH_496_20</idno><idno type="wicri:Area/Main/Corpus">001504</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001504</idno><idno type="wicri:Area/Main/Curation">001504</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001504</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?</title><author><name sortKey="Nina, Praveen Balabaskaran" sort="Nina, Praveen Balabaskaran" uniqKey="Nina P" first="Praveen Balabaskaran" last="Nina">Praveen Balabaskaran Nina</name><affiliation wicri:level="1"><nlm:affiliation>Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu</wicri:regionArea></affiliation></author><author><name sortKey="Dash, Aditya Prasad" sort="Dash, Aditya Prasad" uniqKey="Dash A" first="Aditya Prasad" last="Dash">Aditya Prasad Dash</name><affiliation wicri:level="1"><nlm:affiliation>Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu</wicri:regionArea></affiliation></author></analytic><series><title level="j">Indian journal of public health</title><idno type="ISSN">0019-557X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antimalarials (administration & dosage)</term><term>Antimalarials (adverse effects)</term><term>Antimalarials (therapeutic use)</term><term>Azithromycin (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Therapy, Combination (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antibactériens (usage thérapeutique)</term><term>Antipaludiques (administration et posologie)</term><term>Antipaludiques (effets indésirables)</term><term>Antipaludiques (usage thérapeutique)</term><term>Association de médicaments (MeSH)</term><term>Azithromycine (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (administration et posologie)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimalarials</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimalarials</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antimalarials</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antipaludiques</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antipaludiques</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Antipaludiques</term><term>Azithromycine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term><term>Betacoronavirus</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32496241</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0019-557X</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>Supplement</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Indian journal of public health</Title><ISOAbbreviation>Indian J Public Health</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?</ArticleTitle><Pagination><MedlinePgn>S125-S127</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijph.IJPH_496_20</ELocationID><Abstract><AbstractText>Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nina</LastName><ForeName>Praveen Balabaskaran</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dash</LastName><ForeName>Aditya Prasad</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Public Health</MedlineTA><NlmUniqueID>0400673</NlmUniqueID><ISSNLinking>0019-557X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chloroquine</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Prophylaxis</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32496241</ArticleId><ArticleId IdType="pii">IndianJPublicHealth_2020_64_6_125_285615</ArticleId><ArticleId IdType="doi">10.4103/ijph.IJPH_496_20</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001504 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001504 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:32496241
|texte= Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32496241" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |